POWER OF ATTORNEY FROM ASSIGNEE

JBB 8/24/64 Reg #35,086 BIOGEN IDEC MA, INC., a corporation of Delaware, having a principal place of business at 14 Cambridge Center, Cambridge, Massachusetts 02142, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on 1) 8/20/04, 2) 8/20/04, 3) 8/20/04 and 4) 8/20/04 of an invention known as Compositions and Methods for Treating Cancer Using IGSF9 and LIV-1 (Attorney Docket No. 2159.0030001/LBB/PAC), that is disclosed and claimed in a patent application of the same title by the inventors 1) Karen McLachlan, 2) Scott Glaser, 3) Robert J. Peach and 4) Anthony Rowe (said application filed on January 27, 2004 at the U.S. Patent and Trademark Office, having Application Number 10/764,604).

798 By #35,086 8/24/64

For the purpose of PAIR, the Customer Number is 26111.

The Assignee hereby appoints Christopher A. Dayton, Esq., Registration No. 35,114 and Ramsey Stewart, Esq., Registration No. 38,322 of Biogen Idec MA, Inc. and the U.S. attorneys associated with CUSTOMER NUMBER 28393 to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith. such attorneys currently being: Robert Greene Sterne, Esq., Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Cornwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michele A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Esq., Registration No. 33,997; Robert E. Sokohl, Esq., Registration No. 36,013; Eric K. Steffe, Esq., Registration No. 36,688; Michael Q. Lee, Esq., Registration No. 35,239; Steven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Lawrence B. Bugaisky, Esq., Registration No. 35,086; Donald J. Featherstone, Esq., Registration No. 33,876; Robert C. Millonig, Esq., Registration No. 34,395; Michael V. Messinger, Esq., Registration No. 37,575; Judith U. Kim, Esq., Registration No. 40,679; Timothy J. Shea, Jr., Esq., Registration No. 41,306; Patrick E. Garrett, Esq., Registration No. 39,987.. The Assignees hereby grant said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

Customer Number 26111
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: BIOGEN IDEC MAZING.
SIGNATURE:

BY: Christopher A. Dayton, Esq

TITLE: Associate General Counsel

DATE: August 20, 2004

283171 1.DOC

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/96 (08-03)

	STATEMENT UNDER 37 CFR 3.73(b) 2159.0030001/LBB/PAC
Applicant/Patent Owner: McLachlan et a	al.
Application No./Patent No.: 10/76	4,604 Filed/Issue Date:
Entitled: Compositions And Methods Fo	r Treating Cancer Using IGSF9 And LIV-1
BIOGEN IDEC MA, Inc. (Name of Assignee)	, a <u>Corporation</u> (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title	, and interest; or
2. an assignee of less than the entire The extent (by percentage) of its or in the patent application patent identified	vnership interest is%
A. [] An assignment from the inventor(s) was recorded in the Patent and Trac a copy thereof is attached.	of the patent application/patent identified above. The assignment demark Office at Reel, Frame, or for which
OR	
assignee as shown below:	of the patent application/patent identified above, to the current
1. From: —————	To:
	ded in the Patent and Trademark Office at
The document was recor	To:
	·
3. From:	To:
	rame, or for which a copy thereof is attached.
[] Additional documents in the	chain of title are listed on a supplemental sheet.
[X] Copies of assignments or other docur [NOTE: A separate copy (i.e., the orig must be submitted to Assignment Div recorded in the records of the PTO. S	ginal assignment document or a true copy of the original document) Ision in accordance with 37 CFR Part 3, if the assignment is to be
The undersigned (whose title is supplied I	pelow) is authorized to act on behalf of the assignee.
August 20, 2004	Christopher A. Dayton
Date	Typed or printed name
858-431-8571	CALL LED
Telephone number	Signature
	Associate General Counsel
	Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form end/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: 1) Karen McLachlan, 2) Scott Glaser, 3) Robert J. Peach and 4) Anthony Rowe, the undersigned inventors hereby sell and assign to BIOGEN IDEC MA, INC., a corporation formed under the laws of Delaware (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as Compositions and Methods for Treating Cancer Using IGSF9 and LIV-1 for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) 8/20/04 2, 2) 8/20/04 3, 3) 8/20/04 3 and 4) 8/20/04 (also known as United States Application No. 10/764,604, filed January 27, 2004), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

19B Ay # 35,086 8/24/04

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant Christopher A. Dayton, Esq., Registration No. 35,114 and Ramsey Stewart, Esq., Registration No. 38,322 of Biogen Idec MA, Inc., and Robert Greene Sterne, Esq., Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Cornwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michele A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Esq., Registration No. 33,997; Robert E. Sokohl, Esq., Registration No. 36,013; Eric K. Steffe, Esq., Registration No. 36,688; Michael Q. Lee, Esq., Registration No. 35,239; Steven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Lawrence B. Bugaisky, Esq., Registration No. 35,086; Donald J. Featherstone, Esq., Registration No. 33,876; Robert C. Millonig, Esq., Registration No. 34,395; Michael V. Messinger, Esq., Registration No. 37,575; Judith U. Kim, Esq., Registration No. 40,679; Timothy J. Shea, Jr., Esq., Registration No. 41,306; Patrick B. Garrett, Esq., Registration No. 39,987.; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed b	y the undersigned inven	tors on the date opposite his/her name.
Date: \$ [20]04	Signature of Inventor:	Kars McLachlan
Date: \$120104	Signature of Inventor:	Sur Man
Date: 8/20/04	Signature of Inventor:	
5/20/04		Robert J. Pead
Date: 8 20/04	Signature of Inventor:	Anthony Rowe
Witnessed before me:		4:
Signature: Olla A. Villamera	Signature	: Sala S. Villanes
Print Name: DERPA A. VILLANUEVA	Print Na	me: DEBPH A VILLANDUM
Address: 3030 CALLAN ROAD	Address:	3030 CALLAN ROAD
54N DIEGO, CA 921:	21	3030 CALLAN ROAD SAN DIESO CA 92121

283163_1.DOC

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION